HUTCHMED Shares Gain After Phase III Sovleplenib Data Presented at EHA
HUTCHMED's stock moved higher in premarket trading after the company presented positive Phase III results for sovleplenib in warm antibody autoimmune hemolytic anemia at the European Hematology Association Congress. The ESLIM-02 trial met its primary endpoint, reporting a markedly greater durable response rate and improvements across several second…